Are you challenged to develop evidence-based, molecular-informed treatment plans for patients with relapsed/refractory acute myeloid leukemia (R/R AML)? Join two AML experts in the second podcast of this learning pathway for a quick review of the latest clinical trial data and guideline recommendations for targeted therapies in the R/R AML treatment setting.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/podcast/targeted-therapy-selection-sequencing-relapsed-refractory-aml
- Start Date: 2024-12-20 06:00:00
- End Date: 2024-12-20 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Rigel Pharmaceuticals, Inc. - Amount: 16666.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest